[
  {
    "ts": "2026-02-24T02:11:21+00:00",
    "headline": "FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation",
    "summary": "FDA accepts Bristol Myers Squibb’s New Drug Application for iberdomide in relapsed or refractory multiple myeloma. The filing has been granted Breakthrough Therapy Designation and Priority Review. Iberdomide is being evaluated for patients with a hard to treat blood cancer where curative options remain limited. For Bristol Myers Squibb, NYSE:BMY, this regulatory step comes at a time when the shares trade around $61.25. Recent returns show the stock up 12.1% over the past 30 days and 14.6%...",
    "url": "https://finance.yahoo.com/news/fda-review-iberdomide-puts-fresh-021121688.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "47798994-ccb7-36d3-a503-03afa20d82bc",
      "content": {
        "id": "47798994-ccb7-36d3-a503-03afa20d82bc",
        "contentType": "STORY",
        "title": "FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation",
        "description": "",
        "summary": "FDA accepts Bristol Myers Squibb’s New Drug Application for iberdomide in relapsed or refractory multiple myeloma. The filing has been granted Breakthrough Therapy Designation and Priority Review. Iberdomide is being evaluated for patients with a hard to treat blood cancer where curative options remain limited. For Bristol Myers Squibb, NYSE:BMY, this regulatory step comes at a time when the shares trade around $61.25. Recent returns show the stock up 12.1% over the past 30 days and 14.6%...",
        "pubDate": "2026-02-24T02:11:21Z",
        "displayTime": "2026-02-24T02:11:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-review-iberdomide-puts-fresh-021121688.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-review-iberdomide-puts-fresh-021121688.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]